Bristol-Myers Squibb employees ride across the U.S. to raise money to support cancer research by Stand Up To Cancer

Bristol-Myers SquibbThe first of seven teams of Bristol-Myers Squibb (NYSE:BMY) employees mounted their bikes in Cannon Beach, OR, today to kick off the 2017 Coast 2 Coast 4 Cancer Ride. Ninety-three novice riders will bike a total of nearly 2,800 miles during the 21-day mission to raise money and awareness for Stand Up To Cancer’s innovative cancer research programs that bring together collaborative teams of scientific researchers to help get new therapies to patients faster.

Bristol-Myers Squibb will match funds raised during the 2017 Coast 2 Coast 4 Cancer Ride dollar-for-dollar up to a total of $500,000. This is the fourth Coast 2 Coast 4 Cancer Ride benefitting Stand Up To Cancer (SU2C). Last year’s Coast 2 Coast 4 Cancer ride raised over $1 million for SU2C research programs.

Katie Couric, award-winning journalist and SU2C co-founder said, "All of us at Stand Up To Cancer are profoundly grateful to the Bristol-Myers Squibb employees as they cycle cross-country. Their commitment honors those who are fighting cancer, as well as those lost to the disease. The riders - and everyone who supports them - are helping SU2C advance research with the hope of one day turning more and more cancer patients into long-term survivors."

This year, Bonni Norwood of Spring Lakes, MI, a cancer survivor herself who hasn’t ridden a bike in 45 years, will ride from Kansas City, MO, to Indianapolis, IN. "While training to ride 75 miles per day is difficult for me, my struggles pale in comparison to those faced by people fighting cancer," said Bonni. "I'm riding for two dear friends who are both young and vibrant, but are currently battling cancer. When I face steep climbs or cross winds, I will dig deep and persevere for them and for all cancer patients."

"Every day, we, at Bristol-Myers Squibb, challenge ourselves individually and collectively as a team to fight cancer," said Teresa Bitetti, senior vice president, U.S. Oncology, Bristol-Myers Squibb. "Our employees who are riding across the country exemplify this passion and purpose - to help drive real change for people impacted by cancer."

Concurrently, seventy-eight Bristol-Myers Squibb employees in Europe will embark on a Country 2 Country 4 Cancer Ride . The Country 2 Country Ride kicks off September 8 in Germany, and spans 3,600 kilometers (2,236 miles) through Switzerland, Italy, France, Spain, and the United Kingdom. Funds raised will support one of eight market-specific cancer-focused charities in Europe.

About Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.

About Stand Up To Cancer
Stand Up To Cancer (SU2C) raises funds to accelerate the pace of research to get new therapies to patients quickly and save lives now. SU2C, a division of the Entertainment Industry Foundation (EIF), a 501(c)(3) charitable organization, was established in 2008 by film and media leaders who utilize the industry’s resources to engage the public in supporting a new, collaborative model of cancer research, and to increase awareness about cancer prevention as well as progress being made in the fight against the disease. As SU2C's scientific partner, the American Association for Cancer Research (AACR) and a Scientific Advisory Committee led by Nobel Laureate Phillip A. Sharp, PhD, conduct rigorous, competitive review processes to identify the best research proposals to recommend for funding, oversee grants administration, and provide expert review of research progress.

Current members of the SU2C Council of Founders and Advisors (CFA) include Katie Couric, Sherry Lansing, Lisa Paulsen, Rusty Robertson, Sue Schwartz, Pamela Oas Williams, Ellen Ziffren, and Kathleen Lobb. The late Laura Ziskin and the late Noreen Fraser are also co-founders. Sung Poblete, PhD, RN, has served as SU2C’s president and CEO since 2011.

Most Popular Now

Most popular vitamin and mineral supplements provi…

The most commonly consumed vitamin and mineral supplements provide no consistent health benefit or harm, suggests a new study led by researchers at St. Michael's Hospital...

AstraZeneca heads to 2018 ASCO Annual Meeting with…

AstraZeneca and MedImmune, its global biologics research and development arm, head to the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, US...

Tiny particles could help fight brain cancer

Glioblastoma multiforme, a type of brain tumor, is one of the most difficult-to-treat cancers. Only a handful of drugs are approved to treat glioblastoma, and the median ...

New approach to immunotherapy leads to complete re…

A novel approach to immunotherapy developed by researchers at the National Cancer Institute (NCI) has led to the complete regression of breast cancer in a patient who was...

Spiolto® Respimat® enables greater physical activi…

Boehringer Ingelheim announced data which add to the growing body of evidence that show Spiolto® (tiotropium/olodaterol) Respimat® enables greater physical activity in pa...

Amgen Foundation and Harvard team up to offer free…

The Amgen Foundation and Harvard University today announced plans to launch a free online science education platform uniquely designed to level the playing field for aspi...

The Pfizer Foundation announces $5 million in gran…

The Pfizer Foundation announced a new $5 million grant commitment to initiatives in low- and middle-income countries that provide family planning access and education for...

Study finds antioxidant-enriched vitamin reduces r…

Researchers at Children's Hospital Colorado (Children's Colorado) and the University of Colorado School of Medicine have found that taking a specially formulated antioxid...

New drugs could also be deployed against lung and …

A new anti-cancer drug may be effective against a wider range of cancers than previously thought. Using a mouse model and samples taken from cancer patients, a team from ...

What would help or hinder patient participation in…

As clinical trials gear up with the aim of attaining the first FDA-approved treatments for mitochondrial disease, a new study reports for the first time what patients and...

Pfizer to expand venture investing with $600 milli…

Pfizer Inc. (NYSE:PFE) today announced it plans to invest $600 million in biotechnology and other emerging growth companies through Pfizer Ventures, the company’s venture...

Update on Phase III clinical trials of lanabecesta…

AstraZeneca and Eli Lilly and Company (Lilly) are discontinuing the global Phase III clinical trials of lanabecestat, an oral beta secretase cleaving enzyme (BACE) inhibi...